Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis

Company Overview

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Key Stats

• Today's Range: €23.86 to €24.50
• 50-Day Range: €19.47 to €24.86
• 52-Week Range: €24.96 to €44.28
• Volume: 3.34 million shs
• Average Volume: N/A
• Market Capitalization: $24.29 billion
• P/E Ratio: N/A
• Dividend Yield: 0.46%
• Price Target: N/A
• Consensus Rating: N/A

BAYN Stock Analysis - Frequently Asked Questions

How have BAYN shares performed this year?

Bayer Aktiengesellschaft's stock was trading at €19.31 on January 1st, 2025. Since then, BAYN shares have increased by 24.5% and is now trading at €24.05.
View the best growth stocks for 2025 here.

What other stocks do shareholders of Bayer Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include Hawkins (HWKN), NVIDIA (NVDA), Meta Platforms (META), Alibaba Group (BABA), Basf (BAS), Volkswagen (VOW3) and Bayerische Motoren Werke Aktiengesellschaft (BMW).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: ETR:BAYN
• CIK: N/A
• Web: www.bayer.com
• Phone: 49 214 30 1
• Fax: N/A
• Employees: 96,931
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): (€0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 4.46
• P/E Growth: 36.39
• Net Income: $-904,331,613.41
• Net Margins: -1.88%
• Pretax Margin: N/A
• Return on Equity: -2.61%
• Return on Assets: 3.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.32
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $48.03 billion
• Price / Sales: 0.51
• Cash Flow: €4.20 per share
• Price / Cash Flow: 5.73
• Book Value: €31.24 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 1,009,583,481
• Free Float: N/A
• Market Cap: $24.28 billion
• Optionable: Not Optionable
• Beta: 0.97